VolitionRx Limited (NYSE American: VNRX) has announced the publication of a peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company claims is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). The study, published in a scientific journal, addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA. By achieving this high level of purity, the technology creates highly enriched tumor DNA datasets that could significantly improve cancer detection and monitoring.
The significance of this breakthrough lies in its potential to transform cancer diagnostics. Traditional liquid biopsies often struggle with low concentrations of ctDNA in the bloodstream, making it difficult to detect early-stage cancers or monitor minimal residual disease. Volition's two-step process combines physical sample enrichment with bioinformatic filtering to produce sequencing datasets with greater than 99% purity. In early validation studies, the technology demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings, suggesting the method's robustness.
Volition estimates that the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications. These figures underscore the commercial potential of the technology, which could enable earlier intervention and better patient outcomes. The company is currently conducting technical evaluations with potential licensing partners and is advancing larger validation studies with oncology key opinion leaders. It is also expanding patent protection for the technology as it explores commercialization pathways.
The publication of this study is a critical milestone for Volition, as it provides independent validation of its approach. The company believes that the Capture-Seq technology could become a cornerstone in the field of liquid biopsy, offering a more accurate and reliable method for detecting cancer at its earliest stages. This is particularly important because early detection is known to improve survival rates and quality of life for cancer patients.
Volition is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it is developing simple, cost-effective blood tests for the detection and monitoring of various diseases, including certain cancers and conditions associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with additional offices in the U.S. and London.
The full press release is available at IBN. For more information about Volition, visit its website at Volition.
